Drug interactions with antiretrovirals and warfarin

Expert Opinion on Drug Safety

Volumn 9, Issue 2, 2010, Pages 215-223

  Liedtke, Michelle D ^a   Rathbun, R Chris ^a  

^a UNIVERSITY OF OKLAHOMA   (United States)

Author keywords

Antiretroviral; CYP2C9; Cytochrome; Drug interaction; HIV; NNRTIs; PIs; Warfarin

Indexed keywords

ABACAVIR; ATAZANAVIR; CYTOCHROME P450 2C9; DARUNAVIR; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; ENFUVIRTIDE; ETRAVIRINE; FOSAMPRENAVIR; INDINAVIR; LAMIVUDINE; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; MARAVIROC; NELFINAVIR; NEVIRAPINE; RALTEGRAVIR; RITONAVIR; SAQUINAVIR; STAVUDINE; TENOFOVIR; TIPRANAVIR; WARFARIN; ZIDOVUDINE; ANTIRETROVIRUS AGENT; CYTOCHROME P450;

ANTICOAGULATION; DEEP VEIN THROMBOSIS; DRUG DOSE COMPARISON; DRUG DOSE TITRATION; DRUG METABOLISM; ENZYME INDUCTION; ENZYME INHIBITION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTERNATIONAL NORMALIZED RATIO; PHARMACOGENOMICS; REVIEW; ANIMAL; DRUG INTERACTION; METABOLISM; PHARMACOGENETICS; PHYSIOLOGY; PROCEDURES;

ANIMALS; ANTI-RETROVIRAL AGENTS; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; HUMANS; PHARMACOGENETICS; WARFARIN;

EID: 77649153303     PISSN: 14740338     EISSN: None     Source Type: Journal    
DOI: 10.1517/14740330903493458     Document Type: Review

References (61)

1. The Antiretroviral Therapy Cohort Collaboration. Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet 2008;372:293-299
2. Pallela FJ Jr, Baker RK, Moorman AC, et al. Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV Outpatient Study. J Acquir Immune Defic Syndr 2006;43:27-34
3. Ansell J, Hirsh J, Poller L, et al. The pharmacology and management of the vitamin K antagonists. Chest 2004;126:204S-33S
4. Yeh RF, Gaver VE, Patterson KB, et al. Lopinavir/ritonavir induces the hepatic activity of cytochrome P450 enzymes CYP2C9, CYP2C19, and CYP1A2 but inhibits the hepatic and intestinal activity of CYP3A as measured by a phenotyping drug cocktail in healthy volunteers. J Acquir Immune Defic Syndr 2006;42:52-60 . Lopinavir/ritonavir cocktail study examining cytochrome P450 enzyme interactions.
5. Vourvahis M, Kashuba AD. Mechanisms of pharmacokinetic and pharmacodynamic drug interactions associated with ritonavir-enhanced tipranavir. Pharmacotherapy 2007;27:888-909
6. Sekar V, Spinosa-Guzman S, Meyvisch P, et al. Cocktail study to investigate the in-vivo drug interaction potential of darunavir coadministered with low-dose ritonavir (DRV/r; RTV) on cytochrome P450 enzymes 2D6, 2C9 and 2C19. Presented at the 9th International Workshop on Clinical Pharmacology of HIV (IWCPHIV), New Orleans, USA, April 7-9 2008
7. Fulco PP, Zingone MM, Higginson RT. Possible antiretroviral therapy-warfarin drug interaction. Pharmacotherapy 2008;28:945-949
8. Dionisio D, Mininni S, Bartolozzi D, et al. Need for increased dose of warfarin in HIV patients taking nevirapine. AIDS 2001;15:277-278
9. Bonora S, Lanzafame M, D'Avolio A, et al. Drug interactions between warfarin and efavirenz or lopinavir-ritonavir in clinical treatment. Clin Infect Dis 2008;46:146-147
10. Gatti G, Alessandrini A, Camera M, et al. Influence of indinavir and ritonavir on warfarin anticoagulant activity. AIDS 1998;12:825-856
11. Knoell KR, Young TM, Cousins ES. Potential interaction involving warfarin and ritonavir. Ann Pharmacother 1998;32:1299-1302
12. Hughes CA, Freitas A, Miedzinski LJ. Interaction between lopinavir/ritonavir and warfarin. CMAJ 2007;177:357-359
13. Newshan G, Tsang P. Ritonavir and warfarin interaction. AIDS 1999;13:1788-1789
14. Darlington MR. Hypoprothrombinemia during concomitant therapy with warfarin and saquinavir. Ann Pharmacother 1997;31:647
15. Ahonkhai A, Gebo K, Streiff M, et al. Venous thromboembolism in patients with HIV/AIDS a case-control study. J Acquir Immune Defic Syndr 2008;48:310-314
16. Copur AS, Smith P, Gomez V, et al. HIV infection is a risk factor for venous thromboembolism. AIDS Patient Care STDS 2002;16:205-209
17. Afessa B, Green W, Chiao J, Frederick W. Pulmonary complications of HIV infection. Chest 1998;113:1225-1229
18. Jacobson M, Dezube B, Aboulafia D. Thrombotic complications in patients infected with HIV in the era of highly active antiretroviral therapy: a case series. CID 2004;39:1214-1222
19. Pelkonen O, Turpeinen M, Hakkola J, et al. Inhibition and induction of human cytochrome P450 enzymes: current status. Arch Toxicol 2008;82:667-715
20. McKinnon R, Sorich M, Ward M. Cytochrome P450 part 1: multiplicity and function. J Pharm Pract Res 2008;38:55-57
21. Ward M, Sorich M, Evans A, McKinnon R. Cytochrome P450 part 3: impact of drug-drug interactions. J Pharm Pract Res 2009;39:55-58
22. Gulseth M, Grice G, Dager W. Pharmacogenomics of warfarin: uncovering a piece of the warfarin mystery. Am J Health Syst Pharm 2009;66:123-133
23. O'Reilly RA. Studies on the optical enantiomorphs of warfarin in man. Clin Pharmacol Ther 1974;16:348-354
24. Breckenridge A,OrmeM,WesselingH, et al. Pharmacokinetics and pharmacodynamics of the enantiomers of warfarin in man. Clin Pharmacol Ther 1974;15:424-430
25. Rettie AE, Korzekwa KR, Kunze KL, et al. Hydroxylation of warfarin by human cDNA-expressed cytochrome P-450: a role for P-4502C9 in the etiology of (S)-warfarin-drug interactions. Chem Res Toxicol 1992;5:54-59
26. Kaminsky LS, Zhang Z-Y. Human P450 metabolism of warfarin. Pharmacol Ther 1997;73:67-74
27. Rettie AE, Wienkers LC, Gonzalez FJ, et al. Impaired (S)-warfarin metabolism catalysed by the R144C allelic variant of CYP2C9. Pharmacogenetics 1994;4:39-42
28. Haining RL, Hunter AP, Veronese ME, et al. Allelic variants of human cytochrome P450 2C9: baculovirus-mediated expression, purification, structural characterization, substrate stereoselectivity, and prochiral selectivity of the wild-type and I359L mutant forms. Arch Biochem Biophys 1996;333:447-458
29. Crespi CL, Miller VP. The R144C change in the CYP2C9*2 allele alters interaction of the cytochrome P450 with NADPH: cytochrome P450 oxidoreductase. Pharmacogenetics 1997;7:203-210
30. Peyvandi F, Spreafico M, Siboni SM, et al. CYP2C9 genotypes and dose requirements during the induction phase of oral anticoagulant therapy. Clin Pharmacol Ther 2004;75:198-203
31. Lindh JD, Lundgren S, Holm L, et al. Several-fold increase in risk of overanticoagulation by CYP2C9 mutations. Clin Pharmacol Ther 2005;78:540-550
32. Joffe HV, Xu R, Johnson FB, et al. Warfarin dosing and cytochrome P450 2C9 polymorphisms. Thromb Haemost 2004;91:1123-1128
33. Takahashi H, Wilkinson GR, Nutescu EA, et al. Different contributions of polymorphisms in VKORC1 and CYP2C9 to intra- and inter-population differences in maintenance dose of warfarin in Japanese, Caucasians and African-Americans. Pharmacogenet Genomics 2006;16:101-110
34. Aquilante CL, Langaee TY, LopezLM,et al. Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochromeP4502C9genepolymorphisms on warfarin dose requirements. Clin Pharmacol Ther 2006;79:291-302
35. Xie HG, Kim RB, Wood AJ, Stein CM. Molecular basis of ethnic differences in drug disposition and response. Annu Rev Pharmacol Toxicol 2001;41:815-850
36. Human Cytochrome P450 Allele Nomenclature Committee. Available from URL: http://www.cypalleles.ki.se/cyp2c9. htm. [Accessed 1 September 2009]
37. Product information. Selzentry (maraviroc). New York, NY: Pfizer Labs, August 2007
38. Tseng A, Chionglo M. Selected properties of maraviroc. Available from URL: http:// www.hivclinic.ca/main/ drugs-properties-files/CCR5-maraviroc. pdf. [Accessed 1 September 2009]
39. Von Moltke LL, Greenblatt DJ, Grassi JM, et al. Protease inhibitors as inhibitors of human cytochromes P450: high risk associated with ritonavir. J Clin Pharmacol 1998;38:106-111
40. Von MoltkeLL,GreenblattDJ,GrandaBW, et al. Inhibition of humancytochrome P450 isoforms by nonnucleoside reverse transcriptase inhibitors. J Clin Pharmacol 2001;41:85-91
41. Dixit V, Hariparsad N, Li F, et al. Cytochrome P450 enzymes and transporters induced by anti-human immunodeficiency virus protease inhibitors in human hepatocytes: implications for predicting clinical drug interactions. Drug Metab Dispos 2007;35:1853-1859 [Epub 16 July 2007]
42. Panel on Antiretroviral Guidelines for Adult and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. November 3, 2008;1-139. Available from: http://www.aidsinfo.nih. gov/ContentFiles/AdultandAdolescentGL. pdf. [Accessed 1 September 2009]
43. Ma Q, Okusanya OO, Smith PF, et al. Pharmacokinetic drug interactions with non-nucleoside reverse transcriptase inhibitors. Expert Opin Drug Metab Toxicol 2005;1:473-485
44. Product information. Intelence (etravirine). Raritan, NJ: Tibotec Therapeutics, 19 January 2008
45. Product information. Viracept (nelfinavir). La Jolla, CA: Agouron Pharmaceuticals, August 2007
46. Product information. Kaletra (lopinavir/ ritonavir). North Chicago, IL: Abbott Laboratories, November 2007
47. Product information. Norvir (ritonavir). North Chicago, IL: Abbott Laboratories, May 2007
48. Product information. Prezista (darunavir). Raritan, NJ: Tibotec Therapeutics, 31 February 2008
49. Shelton M, Cloen D, Becker M, et al. Evaluation of the pharmacokinetic interactions between phenytoin and nelfinavir in healthy volunteers at steady state (abstract 426). Presented at: 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, September 17-20, 2000
50. Honda M, Yasuoka A, Aoki M, Oka S. A generalized seizure following initiation of nelfinavir in a patient with human immunodeficiency virus type I infection, suspected due to interaction between nelfinavir and phenytoin. Intern Med 1999;38:302-303
51. Kumar GN, Rodrigues AD, Buko AM, Denissen JF. Cytochrome P450-mediated metabolism of the HIV-1 protease inhibitor ritonavir (ABT-538) in human liver microsomes. J Pharmacol Exp Ther 1996;277:423-431
52. Eagling VA, Back DJ, Barry MG. Differential inhibition of cytochrome P450 isoforms by the protease inhibitors, ritonavir, saquinavir and indinavir. Br J Clin Pharmacol 1997;44:190-194
53. Boehringer Ingelheim Pharmaceuticals, Inc. Tipranavir. Antiviral drugs advisory committee (AVDAC) briefing document, NDA 21-814. Ridgefield, CT; 2005
54. Product information. Aptivus (tipranavir). Ridgefield, CT: Boehringer Ingelheim Pharmaceuticals, June 2008
55. Product information. Reyataz (atazanavir). Princeton, NJ: Bristo-Myers Squibb Company, November 2009
56. Product information. Lexiva (fosamprenavir). Research Triangle Park, NC: GlaxoSmithKline, September 2009
57. Product information. Crixivan (indinavir). Whitehouse Station, NJ: Merck and Company, Inc., October 2008
58. Voora D, McLeod HL, Eby C, Gage BF. The pharmacogenetics of coumarin therapy. Pharmacogenomics 2005;6:503-513
59. LLerena A, Dorado P, O'Kirwan F, et al. Lower frequency of CYP2C9*2 in Mexican-Americans compared to Spaniards. Pharmacogenomics J 2004;4:403-406
60. Wu A, Wang P, Smith A, et al. Dosing algorithm for warfarin using CYP2C9 and VKORC1 genotyping from a multi-ethnic population:comparisonwithother equations. Pharmacogenomics 2008;9:169-178
61. Xie H, Prasad H, Landau R, et al. Frequency of the defective CYP2C9 variant alleles in different ethnic groups. Clin Pharmacol Ther 2002;71:P102